Life sciences organizations are advancing digital initiatives to accelerate innovation in R&D, diagnostics, and regulatory processes. But despite significant investment in AI, ML, and cloud platforms, many efforts stall due to fragmented data, regulatory complexity, and a lack of alignment between digital tools and clinical workflows.
This report distils executive conversations across the Pharmaceutical, BioTech, and MedTech sectors to uncover what is holding digital transformation back and outlines a practical path forward rooted in interoperability, data governance, and trust-building.
Life sciences leaders agree AI is transformative but face significant hurdles around data quality, technical readiness, and regulatory clarity.
Without consistent data standards and FHIR or HL7 compliance, even the most advanced tools struggle to scale in real-world clinical environments.
Digital health tools must fit into clinician and researcher workflows. Learn how to design with integration in mind to earn stakeholder trust.
AI-driven diagnostics and patient-facing solutions may be classified as medical devices. Ignoring compliance risks early on can lead to costly delays later.
The report introduces a six-step process to assess enterprise readiness across systems, data, workflows, and governance.
